Press releases
- Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
- BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
- BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
- Pi Health Raises Over $30M in Series A to Revolutionize Cancer Care and Clinical Trials
- First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
- BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
- BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
- BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
- BeiGene to Present at Upcoming Investor Conferences
- BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
More ▼
Key statistics
As of last trade, Beigene Ltd (49BA:STU) traded at 133.00, 13.68% above the 52 week low of 117.00 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 133.00 |
---|---|
High | 133.00 |
Low | 133.00 |
Bid | 134.00 |
Offer | 136.00 |
Previous close | 126.00 |
Average volume | 8.78 |
---|---|
Shares outstanding | 104.49m |
Free float | 102.78m |
P/E (TTM) | -- |
Market cap | 15.78bn USD |
EPS (TTM) | -8.50 USD |
Data delayed at least 15 minutes, as of Apr 24 2024.
More ▼